Screening for Hepatocellular Carcinoma: The Role of Alpha-fetoprotein and Ultrasound with and without Ultrasound Contrast Agents

Author: Patel Nayna   Lim Adrian K. P.   Blomley Martin J. K.   Sidhu Paul   Taylor-Robinson Simon D.  

Publisher: Maney Publishing

ISSN: 1743-1344

Source: Ultrasound, Vol.13, Iss.4, 2005-11, pp. : 219-225

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The increasing incidence of hepatocellular carcinoma (HCC) is becoming a considerable problem in the UK and worldwide. Although there is no national surveillance programme, increasing evidence shows that surveillance programmes may be beneficial and potentially cost-effective. Small, non-symptomatic HCCs that could be detected on regular ultrasound screening are amenable to treatment, including liver transplantation, surgical resection and radio frequency ablation with good 5-year survival rates. However, large tumours, greater than 5 cm, have a poor prognosis and treatment is only palliative. Therefore, the identification of small lesions through a formalized liver ultrasound surveillance programme together with serum alpha-fetoprotein (AFP) may be useful.